TY  - BOOK
AU  - Walaa Ahmed Mohamed Eldakroury
AU  - Howida Kamal Ibrahim , 
AU  - Mahmoud Mohamed Ghorab , 
TI  - Lornoxicam colon targeting solid dosage form, design, formulation and evaluation / 
PY  - 2016///
CY  - Cairo : 
PB  - Walaa Ahmed Mohamed Eldakroury , 
KW  - Lornoxicam colon
KW  - Solid dosage
KW  - Targeting
N1  - Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics; Issued also as CD
N2  - Non steroidal anti-inflammatory drugs (NSAIDs) got high importance as they inhibit the  progression of cancer especially colon cancer. They can reduce the size of current tumor;  increase the efficiency of anticancer agents and radiotherapy. However, long-term uses of  non-selective NSAIDs can lead to gastrointestinal toxicity from sustained inhibition COX.  Lornoxicam is a non steroidal anti-inflammatory drug of oxicam class and it has the same  side effects of this group when taken orally and has a relatively short plasma half-life (3 to 4  h) which makes it a good candidate for colon targeting. It could avoid the systemic side  effects, enhance its low oral bioavailability due to hepatic first pass metabolism and delay  drug release to target the colon and lower the extent of colorectal carcinomas. The present  study was carried out to develop oral colon targeted drug delivery systems for Lornoxicam  utilizing many strategies as pH sensitive, pressure dependent, microbially triggered and time  dependent enteric coating of granules, tablet and beads
UR  - http://172.23.153.220/th.pdf
ER  -